New drug BM230 enters first human trial for Hard-to-Treat cancers

NCT ID NCT06644300

Recruiting now Disease control Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug, BM230, in people with advanced solid tumors, especially those linked to HER2. The study has two parts: first, finding the safest dose, then expanding to see how well it works. About 123 participants will be enrolled worldwide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BM230
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that are HER2-related.
What could go wrong: This is a very early Phase 1 trial, so safety and effectiveness are not yet known. It may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer gastric cancer neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Fudan Unversity Zhongshan Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Icon Cancer Centre - South Brisbane
RECRUITING

Brisbane, Queensland, 4101, Australia
Monash Health - Monash Medical Centre
RECRUITING

Monash, Victoria, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Adelaide, South Australia, Australia
The first Affiliated Hospital of Bengbu Medical University
RECRUITING

Bengbu, Anhui, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.